β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand

Journal of Medicinal Chemistry

Volumn 57, Issue 22, 2014, Pages 9370-9382

  O'Boyle, Niamh M ^a,b   Pollock, Jade K ^b   Carr, Miriam ^a   Knox, Andrew J S ^b   Nathwani, Seema M ^b   Wang, Shu ^a   Caboni, Laura ^b   Zisterer, Daniela M ^b   Meegan, Mary J ^a  

^a University College Dublin   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(4 HYDROXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 1,3,4 TRIS(4 HYDROXYPHENYL)AZETIDIN 2 ONE; 1,4 BIS(4 BENZYLOXYPHENYL)AZETIDIN 2 ONE; 1,4 BIS(4 HYDROXYPHENYL) 3 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 1,4 BIS(4 HYDROXYPHENYL) 3 (NAPHTHALEN 2 YL)AZETIDIN 2 ONE; 1,4 BIS(4 HYDROXYPHENYL) 3 PHENOXYAZETIDIN 2 ONE; 1,4 BIS(4 HYDROXYPHENYL) 3 PHENYLAZETIDIN 2 ONE; 1,4 BIS(4 HYDROXYPHENYL) 3,3 DIPHENYLAZETIDIN 2 ONE; 1,4 BIS(4 HYDROXYPHENYL)AZETIDIN 2 ONE; 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [(HYDROXY 4 HYDROXYPHENYL)METHYL] 4 (4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (4 HYDROXYPHENYL)METHYL] 1,4 BIS(4 HYDROXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (4 HYDROXYPHENYL)METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL]METHYL 4 (4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)AZETIDIN 2 ONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BETA LACTAM DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NOCODAZOLE; PACLITAXEL; PROTEIN BCL 2; PROTEIN MCL 1; TUBULIN; UNCLASSIFIED DRUG; BETA LACTAM; ESTROGEN; ESTROGEN RECEPTOR ALPHA, HUMAN; ESTROGEN RECEPTOR ANTAGONIST; LACTATE DEHYDROGENASE; LIGAND; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; PROTEIN BINDING; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ALKYLATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CYCLE G2 PHASE; CHEMICAL ANALYSIS; CRYSTAL STRUCTURE; DEBENZYLATION; DEPOLYMERIZATION; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HYDROPHOBICITY; IC50; MCF 7 CELL LINE; MICROTUBULE ASSEMBLY; PROTEIN EXPRESSION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; CELL DIVISION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; COMPUTER SIMULATION; MEDICINAL CHEMISTRY; PROCEDURES;

APOPTOSIS; BETA-LACTAMS; CELL DIVISION; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ANTAGONISTS; ESTROGEN RECEPTOR BETA; ESTROGENS; G2 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; L-LACTATE DEHYDROGENASE; LIGANDS; MCF-7 CELLS; MODELS, MOLECULAR; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; SOFTWARE; TETRAZOLIUM SALTS; THIAZOLES; TUBULIN;

EID: 84913550591     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500670d     Document Type: Article

References (68)

1. Meegan, M. J.; Lloyd, D. G. Advances in the Science of Estrogen Receptor Modulation Curr. Med. Chem. 2003, 101, 181-210
2. Pike, A. C. W. Lessons Learnt from Structural Studies of the Oestrogen Receptor Best Pract. Res., Clin. Endocrinol. Metab. 2006, 20 (1) 1-14
3. Anderson, W. F.; Chatterjee, N.; Ershler, W. B.; Brawley, O. W. Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database Breast Cancer Res. Treat. 2002, 76, 27-36
4. Powles, T. J. Opinion: Anti-Oestrogenic Prevention of Breast Cancer: the Make or Break Point Nat. Rev. Cancer 2002, 2 (10) 787
5. Ali, S.; Coombes, R. C. Endocrine Responsive Breast Cancer and Strategies for Combating Resistance Nat. Rev. Cancer 2002, 2 (2) 101-112
6. Jordan, V. C. New Insights into the Metabolism of Tamoxifen and its Role in the Treatment and Prevention of Breast Cancer Steroids 2007, 72 (13) 829-842
7. Jordan, V. C. Chemoprevention of Breast Cancer with Selective Oestrogen Receptor Modulators Nat. Rev. Cancer 2007, 7, 46-53
8. CG164. Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. National Institute for Clinical Excellence; http://publications.nice.org.uk/familial-breast-cancer-cg164 (accessed April 29, 2014).
9. Cauley, J. A.; Norton, L.; Lippman, M. E.; Eckert, S.; Krueger, K. A.; Purdie, D. W.; Farrerons, J.; Karasik, A.; Mellstrom, D.; Ng, K.; Stepan, J. J.; Powles, T. J.; Morrow, M.; Costa, A.; Silfen, S. L.; Walls, E. L.; Schmitt, H.; Muchmore, D. B.; Jordan, V. C. Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial Breast Cancer Res. Treat. 2001, 65 (2) 125-134
10. Gennari, L.; Merlotti, D.; Martini, G.; Nuti, R. Lasofoxifene: a Third-Generation Selective Estrogen Receptor Modulator for the Prevention and Treatment of Osteoporosis Expert Opin. Invest. Drugs 2006, 15 (9) 1091-1103
11. Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Nishiguchi, G.; Carlson, K.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Pyrazole Ligands: Structure-Affinity/Activity Relationships and Estrogen Receptor-α-Selective Agonists J. Med. Chem. 2000, 43 (26) 4934-4947
12. Renaud, J.; Bischoff, S. F.; Buhl, T.; Floersheim, P.; Fournier, B.; Geiser, M.; Halleux, C.; Kallen, J.; Keller, H.; Ramage, P. Selective Estrogen Receptor Modulators with Conformationally Restricted Side Chains. Synthesis and Structure-Activity Relationship of ER-Selective Tetrahydroisoquinoline Ligands J. Med. Chem. 2005, 48 (2) 364-379
13. Labrie, F.; Labrie, C.; Bélanger, A.; Simard, J.; Gauthier, S.; Luu-The, V.; Mérand, Y.; Giguere, V.; Candas, B.; Luo, S.; Martel, C.; Singh, S. M.; Fournier, M.; Coquet, A.; Richard, V.; Charbonneau, R.; Charpenet, G.; Tremblay, A.; Tremblay, G.; Cusan, L.; Veilleux, R. EM-652 (SCH 57068), a Third Generation SERM acting as Pure Antiestrogen in the Mammary Gland and Endometrium J. Steroid Biochem. Mol. Biol. 1999, 69 (1-6) 51-84
14. Kim, S.; Wu, J. Y.; Birzin, E. T.; Frisch, K.; Chan, W.; Pai, L.-Y.; Yang, Y. T.; Mosley, R. T.; Fitzgerald, P. M. D.; Sharma, N.; Dahllund, J.; Thorsell, A.-G.; DiNinno, F.; Rohrer, S. P.; Schaeffer, J. M.; Hammond, M. L. Estrogen Receptor Ligands. II. Discovery of Benzoxathiins as Potent, Selective Estrogen Receptor α Modulators J. Med. Chem. 2004, 47 (9) 2171-2175
15. Malamas, M. S.; Manas, E. S.; McDevitt, R. E.; Gunawan, I.; Xu, Z. B.; Collini, M. D.; Miller, C. P.; Dinh, T.; Henderson, R. A.; Keith, J. C.; Harris, H. A. Design and Synthesis of Aryl Diphenolic Azoles as Potent and Selective Estrogen Receptor-beta Ligands J. Med. Chem. 2004, 47 (21) 5021-5040
16. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Novel Structural Templates for Estrogen-Receptor Ligands and Prospects for Combinatorial Synthesis of Estrogens Chem. Biol. 1999, 6 (4) 205-219
17. Wang, P.; Min, J.; Nwachukwu, J. C.; Cavett, V.; Carlson, K. E.; Guo, P.; Zhu, M.; Zheng, Y.; Dong, C.; Katzenellenbogen, J. A.; Nettles, K. W.; Zhou, H.-B. Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide J. Med. Chem. 2012, 55 (5) 2324-2341
18. Meegan, M. J.; Carr, M.; Knox, A. J. S.; Zisterer, D. M.; Lloyd, D. G. Beta-Lactam Type Molecular Scaffolds for Antiproliferative Activity: Synthesis and Cytotoxic Effects in Breast Cancer Cells J. Enzyme Inhib. Med. Chem. 2008, 23 (5) 668-685
19. Jordan, M. A. Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin Curr. Med. Chem.: Anti-Cancer Agents 2002, 2 (1) 1-17
20. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm J. Med. Chem. 2005, 48 (21) 6523-6543
21. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: Challenges and Opportunities in Drug Discovery J. Med. Chem. 2014, 57 (19) 7874-7887
22. O'Boyle, N. M.; Meegan, M. J. Designed Multiple Ligands for Cancer Therapy Curr. Med. Chem. 2011, 18 (31) 4722-4737
23. LoRusso, P. M.; Weiss, D.; Guardino, E.; Girish, S.; Sliwkowski, M. X. Rastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer Clin. Cancer Res. 2011, 17 (20) 6437-6447
24. Nathan, F. E.; Berd, D.; Sato, T.; Mastrangelo, M. J. Paclitaxel and Tamoxifen Cancer 2000, 88 (1) 79-87
25. Carr, M.; Greene, L. M.; Knox, A. J. S.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Lead Identification of Conformationally Restricted beta-Lactam type Combretastatin Analogues: Synthesis, Antiproliferative Activity and Tubulin Targeting Effects Eur. J. Med. Chem. 2010, 45 (12) 5752-5766
26. O'Boyle, N. M.; Carr, M.; Greene, L. M.; Bergin, O.; Nathwani, S. M.; McCabe, T.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Synthesis and Evaluation of Azetidinone Analogues of Combretastatin A-4 as Tubulin Targeting Agents J. Med. Chem. 2010, 53 (24) 8569-8584
27. O'Boyle, N. M.; Greene, L. M.; Bergin, O.; Fichet, J.-B.; McCabe, T.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Synthesis, Evaluation and Structural Studies of Antiproliferative Tubulin-Targeting Azetidin-2-ones Bioorg. Med. Chem. 2011, 19, 2306-2325
28. O'Boyle, N. M.; Carr, M.; Greene, L. M.; Knox, A. J. S.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Synthesis, Biochemical and Molecular Modelling Studies of Antiproliferative Azetidinones causing Microtubule Disruption and Mitotic Catastrophe Eur. J. Med. Chem. 2011, 46 (9) 4595-4607
29. Tripodi, F.; Pagliarin, R.; Fumagalli, G.; Bigi, A.; Fusi, P.; Orsini, F.; Frattini, M.; Coccetti, P. Synthesis and Biological Evaluation of 1,4-Diaryl-2-azetidinones as Specific Anticancer Agents: Activation of Adenosine Monophosphate Activated Protein Kinase and Induction of Apoptosis J. Med. Chem. 2012, 55 (5) 2112-2124
30. Clader, J. W.; Burnett, D. A.; Caplen, M. A.; Domalski, M. S.; Dugar, S.; Vaccaro, W.; Sher, R.; Browne, M. E.; Zhao, H.; Burrier, R. E.; Salisbury, B.; Davis, H. R., Jr. 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus J. Med. Chem. 1996, 39 (19) 3684-3693
31. Bisacchi, G. S.; Slusarchyk, W. A.; Bolton, S. A.; Hartl, K. S.; Jacobs, G.; Mathur, A.; Meng, W.; Ogletree, M. L.; Pi, Z.; Sutton, J. C.; Treuner, U.; Zahler, R.; Zhao, G.; Seiler, S. M. Synthesis of Potent and Highly Selective Nonguanidine Azetidinone Inhibitors of Human Tryptase Bioorg. Med. Chem. Lett. 2004, 14 (9) 2227-2231
32. Georg, G. I. The Organic Chemistry of Beta-Lactams; VCH Publishers, Inc.: New York, 1992.
33. Palomo, C.; Aizpurua, J. M.; Ganboa, I.; Oiarbide, M. Asymmetric Synthesis of Beta-Lactams Through the Staudinger Reaction and Their Use as Building Blocks of Natural and Nonnatural Products Curr. Med. Chem. 2004, 11 (14) 1837-1879
34. Ocampo, R.; Dolbier, J. W. R. The Reformatsky Reaction in Organic Synthesis. Recent Advances Tetrahedron 2004, 60 (42) 9325-9374
35. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The Estradiol Pharmacophore: Ligand Structure-Estrogen Receptor Binding Affinity Relationships and a Model for the Receptor Binding Site Steroids 1997, 62 (3) 268-303
36. Otto, H.-H.; Mayrhofer, R.; Bergmann, H.-J. Darstellung und Stereochemie von 3-(α-Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen Liebigs Ann. Chem. 1983, 7, 1152-1161
37. Invitrogen PolarScreen Estrogen Receptor alpha Competitor Assay, Green; http://tools.lifetechnologies.com/content/sfs/manuals/polarscreen-er-alpha-green-man.pdf (accessed April 29, 2014).
38. Invitrogen PolarScreen Estrogen Receptor beta Competitor Assay, Green. http://tools.lifetechnologies.com/content/sfs/manuals/polarscreen-er-beta-green-man.pdf (accessed April 29, 2014).
39. Molecular Operating Environment (MOE) v 2011.10; Chemical Computing Group Inc.; 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7.
40. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen Cell 1998, 95 (7) 927-937
41. Wärnmark, A.; Treuter, E.; Gustafsson, J.-Å.; Hubbard, R. E.; Brzozowski, A. M.; Pike, A. C. W. Interaction of Transcriptional Intermediary Factor 2 Nuclear Receptor Box Peptides with the Coactivator Binding Site of Estrogen Receptor α J. Biol. Chem. 2002, 277 (24) 21862-21868
42. Lubczyk, V.; Bachmann, H.; Gust, R. Investigations on Estrogen Receptor Binding. The Estrogenic, Antiestrogenic, and Cytotoxic Properties of C2-Alkyl-Substituted 1,1-Bis(4-hydroxyphenyl)-2-phenylethenes J. Med. Chem. 2002, 45 (24) 5358-5364
43. Zhou, H.-B.; Comninos, J. S.; Stossi, F.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure J. Med. Chem. 2005, 48 (23) 7261-7274
44. Andreu, J. M.; Perez-Ramirez, B.; Gorbunoff, M. J.; Ayala, D.; Timasheff, S. N. Role of the Colchicine Ring A and Its Methoxy Groups in the Binding to Tubulin and Microtubule Inhibition Biochemistry 1998, 37 (23) 8356-8368
45. Wang, L. G.; Liu, X. M.; Kreis, W.; Budman, D. R. The Effect of Antimicrotubule Agents on Signal Transduction Pathways of Apoptosis: a Review Cancer Chemother. Pharmacol. 1999, 44 (5) 355-361
46. Lennon, J. C.; Bright, S. A.; Carroll, E.; Butini, S.; Campiani, G.; O'Meara, A.; Williams, D. C.; Zisterer, D. M. The Novel Pyrrolo-1,5-benzoxazepine, PBOX-6, Synergistically Enhances the Apoptotic Effects of Carboplatin in Drug Sensitive and Multidrug Resistant Neuroblastoma Cells Biochem. Pharmacol. 2014, 87 (4) 611-624
47. Greene, L. M.; Nathwani, S. M.; Bright, S. A.; Fayne, D.; Croke, A.; Gagliardi, M.; McElligott, A. M.; O'Connor, L.; Carr, M.; Keely, N. O.; O'Boyle, N. M.; Carroll, P.; Sarkadi, B.; Conneally, E.; Lloyd, D. G.; Lawler, M.; Meegan, M. J.; Zisterer, D. M. The Vascular Targeting Agent Combretastatin-A4 and a Novel cis-Restricted Beta-Lactam Analogue, CA-432, Induce Apoptosis in Human Chronic Myeloid Leukemia Cells and Ex Vivo Patient Samples Including Those Displaying Multidrug Resistance J. Pharmacol. Exp. Ther. 2010, 335 (2) 302-313
48. Juin, P.; Geneste, O.; Gautier, F.; Depil, S.; Campone, M. Decoding and Unlocking the BCL-2 Dependency of Cancer Cells Nat. Rev. Cancer 2013, 13 (7) 455-465
49. Parihar, S.; Kumar, A.; Chaturvedi, A. K.; Sachan, N. K.; Luqman, S.; Changkija, B.; Manohar, M.; Prakash, O.; Chanda, D.; Khan, F.; Chanotiya, C. S.; Shanker, K.; Dwivedi, A.; Konwar, R.; Negi, A. S. Synthesis of Combretastatin A4 Analogues on Steroidal Framework and their Anti-breast Cancer Activity J. Steroid Biochem. Mol. Biol. 2013, 137, 332-344
50. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafssons, J.-A.; Carlquist, M. Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor Nature 1997, 389, 753-758
51. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into Tubulin Regulation from a Complex with Colchicine and a Stathmin-like Domain Nature 2004, 428 (6979) 198-202
52. Rahaim, R. J.; Maleczka, R. E. Pd-Catalyzed Silicon Hydride Reductions of Aromatic and Aliphatic Nitro Groups Org. Lett. 2005, 7 (22) 5087-5090
53. Masui, M.; Ohmori, H. Anodic Oxidation of Schiff's Bases. Part II. Anodic Pyridination of N-Benzylidene-p-anisidines in Acetonitrile J. Chem. Soc., Perkin Trans. 2 1972, 1882-1886
54. Palomo, C.; Cossio, F. P.; Arrieta, A.; Odriozola, J. M.; Oiarbide, M.; Ontoria, J. M. The Reformatsky Type Reaction of Gilman and Speeter in the Preparation of Valuable Beta-Lactams in Carbapenem Synthesis: Scope and Synthetic Utility J. Org. Chem. 1989, 54 (24) 5736-5745
55. GraphPad Prism, 4.0; GraphPad Software: San Diego, California, USA, 2009.
56. Invitrogen LanthaScreen TR-FRET Estrogen Receptor alpha Coactivator Assay; http://www.lifetechnologies.com/order/catalog/product/PV4544 (accessed April 29, 2014).
57. Promega CytoTox 96® Non-Radioactive Cytotoxicity Assay Technical Bulletin; http://worldwide.promega.com/~/media/Files/Resources/Protocols/Technical%20Bulletins/0/CytoTox%20NonRadioactive%20Cytotoxicity%20Assay%20Protocol.pdf (accessed April 29, 2014).
58. Minotti, A. M.; Barlow, S. B.; Cabral, F. Resistance to Antimitotic Drugs in Chinese Hamster Ovary Cells Correlates with Changes in the Level of Polymerized Tubulin J. Biol. Chem. 1991, 266 (6) 3987-3994
59. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic Generation of 3D-Atomic Coordinates for Organic Molecules Tetrahedron Comput. Methodol. 1990, 3, 537-547
60. Quacpac, v 1.6.3.1; OpenEye Scientific Software, Inc.; Santa Fe, NM, USA.
61. Ellingson, B. A.; Geballe, M. T.; Wlodek, S.; Bayly, C. I.; Skillman, A. G.; Nicholls, A. Efficient Calculation of SAMPL4 Hydration Free Energies Using OMEGA, SZYBKI, QUACPAC, and Zap TK2014 J. Comput.-Aided Mol. Des. 2014, 28 (3) 289-298
62. Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database J. Chem. Inf. Model. 2010, 50, 572-584
63. Hawkins, P. C. D.; Nicholls, A. Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures J. Chem. Inf. Model. 2012, 52, 2919-2936
64. McGann, M. FRED and HYBRID Docking Performance on Standardized Datasets J. Comput.-Aided Mol. Des. 2012, 26, 897-906
65. Vajdos, F. F.; Hoth, L. R.; Geoghegan, K. F.; Simons, S. P.; LeMotte, P. K.; Danley, D. E.; Ammirati, M. J.; Pandit, J. The 2.0 Å Crystal Structure of the ERα Ligand-Binding Domain Complexed with Lasofoxifene Protein Sci. 2007, 16 (5) 897-905
66. Prota, A. E.; Danel, F.; Bachmann, F.; Bargsten, K.; Buey, R. M.; Pohlmann, J.; Reinelt, S.; Lane, H.; Steinmetz, M. O. The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization J. Mol. Biol. 2014, 426 (8) 1848-1860
67. Akama, T.; Shida, Y.; Sugaya, T.; Ishida, H.; Gomi, K.; Kasai, M. Novel 5-Aminoflavone Derivatives as Specific Antitumor Agents in Breast Cancer J. Med. Chem. 1996, 39 (18) 3461-3469
68. Bardon, S.; Vignon, F.; Montcourrier, P.; Rochefort, H. Steroid Receptor-mediated Cytotoxicity of an Antiestrogen and an Antiprogestin in Breast Cancer Cells Cancer Res. 1987, 47 (5) 1441-1448